Advertisement

Dermatitis Herpetiformis Duhring

  • Christian Rose
  • Detlef Zillikens

Summary

Dermatits herpetiformis (DH) is a pruritic autoimmune subepidermal bullous disease and is considered as a specific cutaneous manifestation of celiac disease (CD). The diagnosis of DH is based on the detection of granular IgA deposits in biopsies of normal-appearing perilesional skin. CD and DH patients have the same genetic predisposition and demonstrate IgA anti-endomysium antibodies in their sera. These antibodies are directed against tissue transglutaminase. Serum levels of IgA antibodies to tissue transglutaminase reflect the extent of histopathologic changes of the small bowel and are routinely assessed in patients with DH and CD. The autoantigen of DH is epidermal transglutaminase which is found in the skin of DH-patients at the same site as the granular IgA deposits. Detection of anti-IgA antibodies against epidermal transglutaminase is a sensitive serological test in the diagnosis of DH. Skin lesions can be controlled by dapsone, but the drug does not affect the small bowel disease. For CD, the treatment of choice is a gluten-free diet that should be maintained for a lifetime. In most patients, the diet eventually results in remission of the skin lesions, a clearance of IgA deposits from the skin and an improvement of the bowel disease. The question why some patients with mild CD produce antibodies against epidermal transglutaminase and develop DH still remains to be elucidated.

Keywords

Celiac Disease Coeliac Disease Bullous Pemphigoid Tissue Transglutaminase Dermatitis Herpetiformis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ackerman AB, Chongchitnant N, Sanchez J, Guo Y, Bennin B, Reichel M, Randall MB (1997) Histologic diagnosis of inflammatory skin diseases, 2nd ed. Williams & Wilkins, Baltimore, pp 271–278Google Scholar
  2. Alexander O’D (1963) The treatment of dermatitis herpetiformis with heparin. Br J Dermatol 75:289–293PubMedCrossRefGoogle Scholar
  3. Alonso-Llamazares J, Gibson LE, Rogers III RS (2007) Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo clinic experience. Int J Dermatol 46:910–919PubMedCrossRefGoogle Scholar
  4. Beutner EH, Chorzelski TP, Reunala TL, Kumar V (1992) Immunopathology of dermatitis herpetiformis. Clin Dermatol 9:295–311CrossRefGoogle Scholar
  5. Beutner EH, Baughman RD, Austin BM, Plunkett RW, Binder WL (2000) A case of dermatitis herpetiformis with IgA endomysial antibodies but negative direct immunofluorescent findings. J Am Acad Dermatol 43:329–332PubMedCrossRefGoogle Scholar
  6. Brow J, Parker F, Weinstein W, Rubin CE (1971) The small intestinal mucosa in dermatitis herpetiformis: severity and distribution of the small intestinal lesion and associated malabsorption. Gastroenterology 60:355–361PubMedGoogle Scholar
  7. Buckley DB, English J, Molloy W, Doyle CT, Welton MJ (1983) Dermatitis herpetiformis: a review of 119 cases. Clin Exp Dermatol 8:477–487PubMedCrossRefGoogle Scholar
  8. Caproni M, Antiga E, Melani L, Fabbri P, The Italian Group of Cutaneous Immunopathology (2009) Guidelines for the diagnosis and treatment of dermatitis herpetiformis. JEADV 23:633–638PubMedGoogle Scholar
  9. Collin P, Pukkala E, Reunala T (1996) Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 38:528–530PubMedCrossRefGoogle Scholar
  10. Cormane RH (1967) Immunofluorescent studies of the skin in lupus erythematosus and other diseases. Pathologica Eur 2:170–180Google Scholar
  11. Corrao G, Corazza GR, Andreani ML, Torchio P, Valentini RA, Galatola G, Quaglino D, Gasbarrini G, di Orio F (1994) Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values. Gut 35:771–775PubMedCrossRefGoogle Scholar
  12. Costello M (1940) Dermatitis herpetiformis treated with sulfapyridine. Arch Dermatol Syphilol 41:134Google Scholar
  13. Chorzelski TP, Jablonska S, Beutner EH, Bear SF, Furey NL (1979) Linear IgA bullous dermatosis. In: Beutner EH, Chorzelski TP, Bear SF (eds) Immunopathology of the skin. 2nd ed. John Wiley & Sons; New York, pp 315–323Google Scholar
  14. Chorzelski TP, Sulej J, Tchorzewska H, Jablonska S, Beutner EH, Kumar V (1983) IgA class endomysium antibodies in dermatitis herpetiformis and coeliac disease. Ann N Y Acad Sci 4:325–334CrossRefGoogle Scholar
  15. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nature Med 3:797–801PubMedCrossRefGoogle Scholar
  16. Dieterich W, Laag E, Schöpper H, Volta U, Ferguson A, Gillett H, Riecken EO, Schuppan D (1998) Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 115:1317–1321PubMedCrossRefGoogle Scholar
  17. Dieterich W, Laag E, Bruckner-Tuderman L, Reunala T, Kárpáti S, Zágoni T, Riecken EO, Schuppan D (1999) Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 113:133–136PubMedCrossRefGoogle Scholar
  18. Duhring LA (1884) Dermatitis herpetiformis. JAMA 3:225–229Google Scholar
  19. Ermacora E, Prampolini L, Tribbia G, Pezzoli G, Gelmetti C, Cucchi G, Tettamanti A, Giunta A, Gianotti F (1986) Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol 15:23–30CrossRefGoogle Scholar
  20. Fraser NG, Kerr NW, Donald D (1973) Oral lesions in dermatitis herpetiformis. Br J Dermatol 89:439–450PubMedCrossRefGoogle Scholar
  21. Fry L, Keir P, McMinn RMH, Cowan JD, Hoffbrand AV (1967) Small-intestinal structure and function and haematological changes in dermatitis herpetiformis. Lancet II:729–734CrossRefGoogle Scholar
  22. Fry L, Seah PP, Riches DJ, Hoffbrand AV (1973) Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet I:288–291CrossRefGoogle Scholar
  23. Fry L, Leonard JN, Swain F, Tucker WFG, Haffenden G, Ring N, McMinn RMH (1982) Long-term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 107:631–640PubMedCrossRefGoogle Scholar
  24. Fry L (1988) Fine points in the management of dermatitis herpetiformis. Semin Dermatol 7:206–211PubMedGoogle Scholar
  25. Fry L (2002) Dermatitis herpetiformis: problems, progress and prospect. Eur J Dermatol 12:523–531PubMedGoogle Scholar
  26. Garioch JJ, Lewis HM, Sargent SA, Leonard JN, Fry L (1994) 25 years’ experience of gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 131:541–545PubMedCrossRefGoogle Scholar
  27. Graeber M, Baker BS, Garioch JJ (1993) The role of cytokines in the generation of skin lesions in dermatitis herpetiformis. Br J Dermatol 129:530–532PubMedCrossRefGoogle Scholar
  28. Green PHR, Cellier C (2007) Celiac disease. N Engl J Med 357:1731–1743PubMedCrossRefGoogle Scholar
  29. Hardman CM, Garioch JJ, Leonard JN, Thomas HJ, Walker MM, Lortan JE, Lister A, Fry L (1997) Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 337:1884–1887PubMedCrossRefGoogle Scholar
  30. Hendrix JD, Karen L, Mangum MT, Zone JJ, Gammon WR (1990) Cutaneous IgA deposits in bullous diseases function as ligands to mediate adherence of activated neutrophils. J Invest Dermatol 94:667–672PubMedCrossRefGoogle Scholar
  31. Hofmann SC, Nashan D, Bruckner-Tuderman L (2009) Petechiae on the fingertips as presenting symptom of dermatitis herpetiformis Duhring. JEADV 23:732–733PubMedGoogle Scholar
  32. Kadunce DP, Meyer LJ, Zone JJ (1989) IgA class antibodies in dermatitis herpetiformis: reaction with tissue antigens. J Invest Dermatol 93:253–258PubMedCrossRefGoogle Scholar
  33. Kárpáti S, Torok E, Kosnai I (1986) Discrete palmar and plantar symptoms in children with dermatitis herpetiformis Duhring. Cutis 3:184–187Google Scholar
  34. Kárpáti S, Meurer M, Stolz W, Schrallhammer K, Krieg T, Braun-Falco O (1990) Dermatitis herpetiformis bodies. Arch Dermatol 126:1469–1474PubMedCrossRefGoogle Scholar
  35. Lear JT, Neary RH, Jones P, Fitzgerald DA, English JS (1997) Risk factors for ischaemic heart disease in patients with dermatitis herpetiformis. J R Soc Med 90:247–249PubMedGoogle Scholar
  36. Leonard J, Haffenden G, Tucker W, Unsworth J, Swain F, McMinn R, Holborow J, Fry L (1983) Gluten challenge in dermatitis herpetiformis. N Engl J Med 308:816–819PubMedCrossRefGoogle Scholar
  37. Lewis HM, Reunala TL, Garioch JJ, Leonard JN, Fry JS, Collin P, Evans D, Fry L (1996) Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 135:363–367PubMedCrossRefGoogle Scholar
  38. Lewis NR, Logan RFA, Hubbard RB, West J (2008) No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 27:1140–1147PubMedCrossRefGoogle Scholar
  39. Olkarinen AL, Reunala T, Zone JJ, Kilstala U, Uitto J (1986) Proteolytic enzymes in blister fluids from patients with dermatitis herpetiformis. Br J Dermatol 114:295–302CrossRefGoogle Scholar
  40. Marks J, Shuster S, Watson AJ (1966) Small bowel changes in dermatitis herpetiformis. Lancet II:1280–1282CrossRefGoogle Scholar
  41. McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L (1989) Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 121:759–762PubMedCrossRefGoogle Scholar
  42. Mobacken H, Kastrup W, Nilsson L. (1984) Incidence and prevalence of dermatitis herpetiformis in Western Sweden. Acta Derm Venereol 64:400–404PubMedGoogle Scholar
  43. Prendiville JS, Esterly NB (1991) Childhood dermatits herpetiformis. Clin Dermatol 9:375–381PubMedCrossRefGoogle Scholar
  44. Reunala T, Collin P (1997) Diseases associated with dermatitis herpetiformis. Br J Dermatol 136:315–318PubMedCrossRefGoogle Scholar
  45. Reunala T, Collin P, Holm K, Pikkarainen P, Miettinen A, Vuolteenaho N, Maki M (1998) Tolerance to oats in dermatitis herpetiformis. Gut 43:490–493PubMedCrossRefGoogle Scholar
  46. Prause C, Richter T, Koletzko S, Uhlig HH, Hauer AC, Stern M, Zimmer KP, Laass MW, Probst C, Schlumberger W, Mothes T (2009) New developments in serodiagnosis of childhood celiac disease: assay of antibodies against deamidated gliadin. Ann N Y Acad Sci 1173:28–35PubMedCrossRefGoogle Scholar
  47. Rose C, Dieterich W, Bröcker EB, Schuppan D, Zillikens D (1999) Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease. J Am Acad Dermatol 61:39–43CrossRefGoogle Scholar
  48. Rose C, Bröcker EB, Krahl D (2003) Dermatitis herpetiformis with flame figures mimicking an arthropod bite. Am J Dermatopathol 25:277–278PubMedCrossRefGoogle Scholar
  49. Rose C, Bröcker EB, Zillikens D (2004) Relevance of histological examination in the diagnosis of autoimmune bullous dermatoses. J Dtsch Dermatol Ges 2:96–104PubMedCrossRefGoogle Scholar
  50. Rose C, Armbruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I (2009) Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 41:957–961CrossRefGoogle Scholar
  51. Rose C, Bröcker EB, Zillikens D (2010) Clinical, histological and immunpathological findings in 32 patients with dermatitis herpetiformis Duhring. J Dtsch Dermatol Ges 8:265–271PubMedCrossRefGoogle Scholar
  52. Sachs JA, Awad J, McCloskey D, Navarrete C, Festenstein H, Elliot E, Walker-Smith JA, Griffiths CE, Leonard JN, Fry L (1986) Different HLA associated gene combinations contribute to susceptibility for coeliac disease and dermatitis herpetiformis. Gut 27:515–520PubMedCrossRefGoogle Scholar
  53. Sárdy M, Odenthal U, Kárpáti S, Paulsson M, Smyth N (1999) Recombinat human tissue transglutaminase ELISA for the diagnosis of gluten-sensitive enteropathy. Clin Chem 45:2142–2149PubMedGoogle Scholar
  54. Sárdy M, Kárpáti S, Merkl B, Paulsson M, Smyth N (2002) Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 195:747–757PubMedCrossRefGoogle Scholar
  55. Seissler J, Borns S, Wohlrab U, Morgenthaler NG, Mothes T, Boehm BO, Scherbaum WA (1999) Antibodies to human tissue transglutaminase measured by radioligand assay: evidence for high diagnostic sensitivity for celiac disease. Horm Metab Res 31:375–379PubMedCrossRefGoogle Scholar
  56. Silvers DN, Juhlin EA, Berczeller PH, McSorley J (1980) Treatment of dermatitis herpetiformis with colchicine. Arch Dermatol 116:1373–1374PubMedCrossRefGoogle Scholar
  57. Shah SAA, Ormerod AD (2000) Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide. Clin Exp Dermatol 25:204–205PubMedCrossRefGoogle Scholar
  58. Smith JB, Tulloch JE, Meyer LJ, Zone JJ (1992) The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol 128:1608–1610PubMedCrossRefGoogle Scholar
  59. Smith JB, Taylor TB, Zone JJ (1992) The site of blister formation in dermatitis herpetiformis is within the lamina lucida. J Am Acad Dermatol 27:209–213PubMedCrossRefGoogle Scholar
  60. Sulkanen S, Halttunen T, Laurila K, Kolho KL, Korponay-Szabo IR, Sarnesto A, Savilahti E, Collin P, Mäki M (1998) Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 115:1322–1328PubMedCrossRefGoogle Scholar
  61. Sugai E, Hwang HJ, Vázquez H, Smecuol E, Niveloni S, Mazure R, Mauriño E, Aeschlimann P, Binder W, Aeschlimann D, Bai JC (2010) New serology assays can detect gluten sensitivity among enteropathy patients seronegative for anti-tissue transglutaminase. Clin Chem 56:661–665PubMedCrossRefGoogle Scholar
  62. Sugai E, Smecuol E, Niveloni S, Vázquez H, Label M, Mazure R, Czech A, Kogan Z, Mauriño E, Bai JC (2006) Celiac disease serology in dermatitis herpetiformis. Which is the best option for detecting gluten sensitivity? Acta Gastroenterol Latinoam 36:197–201PubMedGoogle Scholar
  63. Swerdlow AJ, Whittaker S, Carpenter LM, English JSC (1993) Mortality and cancer incidence in patients with dermatitis herpetiformis: a cohort study. Br J Dermatol 129:140–144PubMedCrossRefGoogle Scholar
  64. Tan CC, Sale JE, Brammer C, Irons RP, Freeman JG (1996) A rare case of dermatitis herpetiformis requiring parenteral heparin for long-term control. Dermatology 192:185–186PubMedCrossRefGoogle Scholar
  65. Van der Meer JB (1969) Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. Br J Dermatol 81:493–503PubMedCrossRefGoogle Scholar
  66. Ventura A, Magazzu G, Greco L for the SIGEP study group for autoimmune disorders in celiac disease (1999) Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. Gastroenterology 117:297–303Google Scholar
  67. Warren SJP, Cockerell CJ (2002) Characterization of a subgroup of patients with dermatitis herpetiformis with nonclassical histologic features. Am J Dermatopathol 24:305–308PubMedCrossRefGoogle Scholar
  68. Zemtsov A, Neldner K (1993) Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. J Am Acad Dermatol 28:505–506PubMedCrossRefGoogle Scholar
  69. Zillikens D, Kawahara Y, Ishiko A, Shimizu H, Mayer J, Rank CV, Liu Z, Giudice GJ, Tran HH, Marinkovich MP, Bröcker EB, Hashimoto T (1996) A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 106:1333–1336PubMedCrossRefGoogle Scholar
  70. Zone JJ, Laurence JM, Peterson MJ (1996) Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol 132:912–918PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2011

Authors and Affiliations

  • Christian Rose
    • 1
  • Detlef Zillikens
    • 1
  1. 1.Department of DermatologyUniversity of LübeckLübeckGermany

Personalised recommendations